KC
ARNA

Kepos Capital’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Kepos Capital’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,744
Closed -$538K – 436
2019
Q3 		$538K Sell
11,744
-5,025
-30% -$282K 0.05% 186
2019
Q2 		$983K Buy
+16,769
New +$867K 0.1% 166

Other funds holding ARNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Kepos Capital's ARNA Position: Q4 2019 in Review

Kepos Capital sold out of Arena Pharmaceuticals Inc (ARNA) in Q4 2019, closing a stake of 11,744 shares — an estimated $538K sold.

Kepos Capital first reported a position in ARNA in Q2 2019 and held it in 2 quarters. The position peaked at $983K in Q2 2019. 226 funds tracked by Wall St. Rank hold ARNA as of Q4 2019.

  • Kepos Capital reported no remaining Arena Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Kepos Capital sold 11,744 Arena Pharmaceuticals Inc shares in Q4 2019, an estimated $538K.
  • Kepos Capital first reported a position in Arena Pharmaceuticals Inc in Q2 2019 and held it in 2 quarters.
  • Kepos Capital's Arena Pharmaceuticals Inc position peaked at $983K in Q2 2019.
  • 226 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q4 2019.

Based on Kepos Capital's 13F filing for Q4 2019, filed 13 Feb 2020.